UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2026

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-40483	81-1822909
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326
(Address of principal executive offices) (Zip Code)

(844) 722-6333
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	ALZN	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Information.

As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the "**Company**") entered into a Master Clinical Trial Agreement (the "**Agreement**") with The General Hospital Corporation d/b/a Massachusetts General Hospital ("**MGH**") to conduct five Phase II clinical trials of AL001. Each of the five trials, one in each of healthy subjects, patients afflicted with Alzheimer's Disease ("**Alzheimer's**"), bipolar disorder ("**BD**"), major depressive disorder ("**MDD**") and post-traumatic stress disorder ("**PTSD**"), is intended to be covered by a separate statement of work ("**SOW**") under the Agreement. To date, the Company has entered into a statement of work for healthy subjects (the "**Healthy SOW**") and patients afflicted with BD (the "**BD SOW**"). In May 2025, the Company initiated the clinical trial relating to the Healthy SOW (the "**Healthy Patient Clinical Trial**"), which clinical portion was completed in November 2025.

In March 2026, the Company initiated the clinical trial relating to the BD SOW (the "**BD Clinical Trial**"). MGH subsequently advised the Company that recruitment had been challenging because the trial's eligibility criteria excluded patients with certain co-morbidities, including diabetes, metabolic syndrome, cardiovascular disease and anxiety disorders, which are highly prevalent in this patient population. To improve enrollment, MGH asked that the Company modify the BD Clinical Trial's eligibility criteria to include patients with such co-morbidities. The Company then made such request to the U.S. Food and Drug Administration (the "**FDA**") to allow the Company to modify enrollment criteria. On October 15, 2026, the Company received written feedback from the FDA, in which the FDA did not support the proposed approach and indicated that efficacy and safety trials may be more appropriate to support a New Drug Application (an "**NDA**"). Specifically, the FDA stated that, "Based on the information you have submitted thus far, it does not appear that you are designing the aforementioned trials to be adequate and well-controlled studies that would be capable of providing substantial evidence of effectiveness for the proposed indications."

In response, the Company paused the BD Clinical Trial on October 21, 2026 to further assess its options and determine the best path forward. Based on the written feedback from the FDA, the Company intends to request a Type B meeting with the FDA, which is a meeting typically held at key decision points in a drug's development. Through this meeting, the Company will seek the FDA's feedback on a revised clinical development plan, which is expected to include ceasing Phase II trials of AL001 and moving directly into a Phase III efficacy and safety trial in BD that would support an NDA. Specifically, the Company will ask the FDA to assess the results of the Healthy Patient Clinical Trial in the context of the Company's completed clinical and nonclinical trials, and current good manufacturing practice work. The Company is preparing a briefing package in support of the Type B meeting and currently anticipates receiving the FDA's feedback by the end of the second quarter of 2027.

In consultation with MGH, the Company considered adding additional healthy subjects to the BD Clinical Trial or moving to additional patient cohorts in the future planned clinical trials of MDD, PTSD and/or Alzheimer's. Ultimately, the Company decided that, for efficiency purposes, it would not commit to any path forward on the BD Clinical Trial before receiving the FDA's feedback. As a result, MGH then advised the Company that it could not keep the BD Clinical Trial paused for the anticipated period and would reassign the staff allocated to the study. On November 11, 2026, MGH delivered written notice to the Company terminating the BD SOW. The Company will receive a refund of approximately $25,000 from MGH of funds previously paid in connection with the BD Clinical Trial but not utilized.

The termination of the BD SOW has no impact on the Healthy SOW or the Healthy Patient Clinical Trial. The Company expects to finalize the clinical study report for the Healthy Patient Clinical Trial and to announce the final results in December 2026. In addition, the termination of the BD SOW has not impact on the Agreement, which otherwise remains in full and effect. Following the FDA's feedback, the Company plans to pursue further clinical studies of AL001 in BD, MDD, PTSD and Alzheimer's.

In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant's judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as "expects," "should," "will," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

Item 9.01 **Financial Statements and Exhibits.**

(d) **Exhibits:**

Exhibit No.	Description
101	Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALZAMEND NEURO, INC.

Dated: November 17, 2026

/s/ Stephan Jackman
Stephan Jackman
Chief Executive Officer